[Epidermal growth factor receptors (EGFR): a new target for anticancer therapy]
| Autor: | M, Gainet, E, Guardiola, A, Dufresne, X, Pivot |
|---|---|
| Jazyk: | francouzština |
| Rok vydání: | 2003 |
| Předmět: |
Clinical Trials as Topic
Biopsy Panitumumab Antibodies Monoclonal Cetuximab Antineoplastic Agents Gefitinib Protein-Tyrosine Kinases Antibodies Monoclonal Humanized Prognosis Survival Analysis ErbB Receptors Gene Expression Regulation Neoplastic Cell Transformation Neoplastic Treatment Outcome Neoplasms Quinazolines Humans Signal Transduction |
| Zdroj: | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 7(3) |
| ISSN: | 1278-3218 |
| Popis: | Epidermal Growth Factor receptor (EGFR) are a key factor for the tumoral proliferation and its tumoral over expression appears to be a powerful prognosis factor. Currently, 2 types of treatments are targeting EGFR: a monoclonal antibodies anti-EGFR and a specific inhibitors of the EGFR tyrosine kinase. The administration of these compound alone or in combination with chemotherapy gives some promising results. These targets as anti-cancer therapy had emerged to be a new perspective for oncology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect